10-K: Tempest Therapeutics Reports Positive Clinical Trial Progress and Outlines Future Strategy in 2024 10-K Filing

Tempest Therapeutics highlights positive clinical trial results for amezalpat and TPST-1495, alongside strategic plans for pipeline expansion and business development in its 2024 10-K filing.

Summary

• Tempest Therapeutics, a clinical-stage biotechnology company, is focused on developing targeted and immune-mediated cancer therapies.
• The company's lead program, amezalpat, is preparing for a pivotal Phase 3 study in first-line hepatocellular carcinoma (HCC).
• Phase 1b/2 clinical study data showed amezalpat improved median overall survival by six months (HR of 0.65) when combined with atezolizumab and bevacizumab compared to the standard of care.
• The FDA provided positive feedback on the Phase 3 clinical trial design for amezalpat, which will use the current Phase 2 dose and schedule.
• The FDA also granted Orphan Drug Designation and Fast Track Designation for amezalpat.
• TPST-1495, the company's second clinical program, is expected to enter Phase 2 development in 2025 for Familial Adenomatous Polyposis (FAP).
• The Cancer Prevention Clinical Trials Network (CP-CTNet) received FDA authorization to initiate an NCI-funded Phase 2 clinical trial evaluating TPST-1495 in FAP patients.
• The company plans to enhance its pipeline through novel oncology target identification and in-licensing opportunities.
• Tempest intends to build a targeted sales force in the United States to support the commercialization of its drug candidates, if approved.
• As of December 31, 2024, the company had 25 employees.
• The company reported net losses of $41.8 million for 2024 and $29.5 million for 2023.
• The company's cash and cash equivalents totaled $30.3 million as of December 31, 2024, expected to fund operations for at least the next 12 months.
• The company will require significant additional capital to fund continued development, including the Phase 3 clinical trial for amezalpat.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. Positive clinical trial results and FDA designations are encouraging, but ongoing losses and the need for additional funding create uncertainty.

Positives

• Amezalpat demonstrated a significant survival benefit in HCC patients.
• The FDA provided positive feedback on the Phase 3 clinical trial design for amezalpat.
• TPST-1495 is advancing into Phase 2 development for FAP.
• The company has a strategy to expand its pipeline through in-licensing and internal research.
• The company has a collaboration agreement with Roche for the development of amezalpat.
• The FDA granted Orphan Drug Designation and Fast Track Designation for amezalpat.

Negatives

• The company has a history of operating losses and expects to continue incurring losses.
• The company will require substantial additional funding to finance its operations.
• The company's ability to raise capital may be limited by applicable laws and regulations.
• The company's common stock is thinly traded and may be volatile.

Risks

• The company may not be able to obtain regulatory approval for its product candidates.
• Clinical trials may be delayed or unsuccessful.
• The company faces significant competition in the biopharmaceutical industry.
• The company may not be able to establish sales and marketing capabilities.
• The company's intellectual property may not be adequately protected.
• The company is subject to extensive government regulation.
• The company may be affected by unstable market and economic conditions.
• The company may be subject to product liability claims.
• The company may be adversely affected by changes in tax laws or regulations.
• The company may be adversely affected by cybersecurity threats.

Future Outlook

The company plans to advance amezalpat into a pivotal Phase 3 study, explore TPST-1495 in a Phase 2 study, enhance its pipeline through in-licensing, and explore business development opportunities to maximize the potential of its pipeline.

Management Comments

• The company's philosophy is to build a company based upon not only good ideas and creative science, but also upon the efficient translation of those ideas into therapies that will improve patients lives.

Industry Context

The biopharmaceutical and immuno-oncology industries are characterized by intense competition and rapid innovation, with many companies developing cancer therapies in various indications.

Comparison to Industry Standards

• The document mentions competitors such as Ono, Adlai Nortye, Merck, Roche, Exelixis, and AstraZeneca, which are also developing treatments for HCC, RCC, and cholangiocarcinoma.
• Amezalpat is described as the first PPAR antagonist in the clinic, differentiating it from other companies' approaches.
• For TPST-1495, the document notes that Adlai Nortye and Ono are developing other clinical-stage EP-4-only antagonists.

Stakeholder Impact

• Shareholders: Potential for increased value through successful drug development, but risk of dilution from future capital raises.
• Employees: Continued employment and potential for equity ownership.
• Patients: Potential for new and effective cancer treatments.
• Suppliers: Continued business relationships for manufacturing and research services.
• Creditors: Repayment obligations under the Loan Agreement with Oxford Finance LLC.

Next Steps

• Advance amezalpat into a pivotal Phase 3 study in first-line HCC patients.
• Explore TPST-1495 in a Phase 2 study in patients with FAP with CP-CTNet in 2025.
• Enhance the pipeline by identifying novel oncology targets and in-licensing opportunities.
• Explore business development opportunities to maximize the potential of the pipeline and extend financial resources.

Key Dates

Keywords

amezalpat, TPST-1495, hepatocellular carcinoma, Familial Adenomatous Polyposis, clinical trials, FDA, Orphan Drug Designation, Fast Track Designation, biotechnology, oncology, PPAR antagonist, EP2/EP4 antagonist, Roche, licensing, pipeline